CIK 0001541157 · Non-accelerated filer<br>Smaller reporting company
Akari Therapeutics Plc
Sign in to watch- Ticker
- AKTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- EIN
- 981034922
- Phone
- (929) 274-7510
- Business address
- 401 EAST JACKSON STREET, SUITE 3300, TAMPA, FL, 33602
- Former names
- Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-28 | Grissinger Michael Director | Grant or award · Stock Option (Right to Buy) | +5,000,000 | 5,000,000 | ||
| 2024-05-31 | Patel Samir Rashmikant Director | Grant or award | +1,326,258,000 | $0.00 | $1.2M | 3,411,495,500 |
| 2024-05-31 | Patel Samir Rashmikant Director | Grant or award · Warrants (Right to Buy) | +1,326,258,000 | $0.00 | $1.2M | 1,326,258,000 |
| 2024-05-31 | Prudo-Chlebosz Raymond Director | Grant or award | +1,326,258,000 | $0.00 | $1.2M | 3,657,838,600 |
| 2024-05-31 | Prudo-Chlebosz Raymond Director | Grant or award · Warrants (Right to Buy) | +1,326,258,000 | $0.00 | $1.2M | 1,326,258,000 |
| 2024-05-01 | DICICCO WENDY F Interim CFO | Grant or award | +158,473,915 | 158,473,915 | ||
| 2024-04-26 | Jacques Rachelle Suzanne Chief Executive Officer | Grant or award | +479,569,892 | 1,018,027,792 | ||
| 2016-06-29 | Cohen Mark S Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-06-29 | Byrne David Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-06-29 | Hill James Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-06-29 | Ungar Stuart Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-06-29 | Williams Donald Allen Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-06-29 | Williams Donald Allen Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-04-22 | Byrne David Director | Grant or award · Options to Purchase Ordinary Shares | +1,300,000 | 1,300,000 | ||
| 2016-03-23 | SHAW ROBERT M General Counsel and Secretary | Grant or award · Options to Purchase Ordinary Shares | +1,800,000 | 1,800,000 | ||
| 2015-11-25 | Ungar Stuart Director | Grant or award · Options to Purchase Ordinary Shares | +1,088,722 | 1,088,722 | ||
| 2015-11-25 | Hill James Director | Grant or award · Options to Purchase Ordinary Shares | +1,068,722 | 1,068,722 | ||
| 2015-11-25 | Shaw Allan Director | Grant or award · Options to Purchase Ordinary Shares | +1,068,722 | 1,068,722 | ||
| 2015-11-25 | Cohen Mark S Director | Grant or award · Options to Purchase Ordinary Shares | +1,028,722 | 1,028,722 | ||
| 2015-09-21 | Shaw Allan Director | Grant or award · Options to Purchase Ordinary Shares | +45,000 | 45,000 |
Page 9 of 11 · 216 trades